Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years-Reference-Cited by-同舟云学术

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

Published:2016-12 Issue:4 Volume:123 Page:592-599
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pinsky Paul F.¹,Prorok Philip C.¹,Yu Kelly²,Kramer Barnett S.¹,Black Amanda²,Gohagan John K.³,Crawford E. David⁴,Grubb Robert L.⁵,Andriole Gerald L.⁵

Affiliation:

1. Division of Cancer Prevention, National Cancer Institute, National Institutes of HealthBethesda Maryland

2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of HealthBethesda Maryland

3. Office of Disease Prevention, National Institutes of HealthBethesda Maryland

4. Department of SurgeryUniversity of Colorado School of MedicineAurora Colorado

5. Division of UrologyWashington University School of MedicineSt. Louis Missouri

Funder

National Cancer Institute

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30474

Reference16 articles.

1. Surveillance Epidemiology and End Results Program. SEER cancer statistics review (CSR) 1975‐2013.http://seer.cancer.gov/csr/1975_2013/. Accessed July 5 2016.

2. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force

3. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

4. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

5. Prostate-Cancer Mortality at 11 Years of Follow-up

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

2. Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare;JCO Clinical Cancer Informatics;2024-08

3. Controversies in prostate cancer screening;Urologic Oncology: Seminars and Original Investigations;2024-08

4. A Novel Liquid Biopsy Method Based on Specific Combinations of Vesicular Markers Allows Us to Discriminate Prostate Cancer from Hyperplasia;Cells;2024-07-31

5. The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area;Annals of Surgical Oncology;2024-07-30